Product Details
| Product Name:
Otenabant |
CAS No.:
686344-29-6 |
| Purity:
99.44% |
Supply Ability:
10g |
| Release date:
2026/04/21 |
Product Introduction
Bioactivity
| Name | Otenabant |
| Description | Otenabant (CP-945598) has been investigated for the treatment of Obesity. |
| In vitro | Otenabant HCl has a low Ki affinity for human CB2 receptors of 7.6 μM[1]. Otenabant HCl inhibits CB1 receptor with moderate unbound microsomal clearance, low hERG affinity, and adequate CNS penetration[2]. |
| In vivo | Otenabant effectively enhances energy expenditure and promotes fat oxidation in rats, alongside reducing the respiratory quotient, indicative of a shift towards greater fat utilization. When administered orally at a dosage of 10 mg/kg, Otenabant results in a notable 9% weight reduction over 10 days in mice with diet-induced obesity, after adjusting for vehicle effects. Additionally, Hydrochloride (HCl) form of Otenabant counteracts behaviors induced by cannabinoid agonists—including altered locomotor activity, hypothermia, analgesia, and catalepsy—triggered by the synthetic CB1 receptor agonist CP-55940. Furthermore, in rodent models, Otenabant HCl demonstrates a dose-dependent appetite-suppressing effect and increases both energy expenditure and fat oxidation. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 10 mg/mL (19.59 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (1.96 mM), Sonication is recommended.
|
| Keywords | Otenabant | Inhibitor | inhibit | CP945598 | CP 945598 | CB1 | CB | CannabinoidReceptor | Cannabinoid Receptor |
| Inhibitors Related | RTICBM-189 | β-Caryophyllene | CB2 modulator 1 | Pregnenolone | CB1 inverse agonist 1 | Pregnenolone acetate | CB1 antagonist 2 | CB2 receptor agonist 2 | AM-1235 | 2,3-Butanediol | Drinabant | AM281 |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Anti-Obesity Compound Library | Anti-Cancer Clinical Compound Library | Neurotransmitter Receptor Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$15.00
|
|
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-13 |
|
|
$15.00
|
|
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-09 |
United States